title: Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
abstract: Traditional chemotherapies, interleukins, phosphorylase inhibitors, and proteasome inhibitors are important therapies available to patients with cutaneous T-cell lymphoma (CTCL). Traditional chemotherapies, both in combination and as single agents, are commonly used in relapsed, refractory CTCLs that behave in an aggressive manner. Interleukins, phosphorylase inhibitors, and proteasome inhibitors are less commonly used but data support a role in patients with more refractory disease.
authors.affiliation: Departments of Dermatology and Pathology, Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.
authors.forename: Catherine G
authors.initials: CG
authors.lastname: Chung
authors.affiliation: James P. Wilmot Cancer Center, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA. Electronic address: bpoligone@gmail.com.
authors.forename: Brian
authors.initials: B
authors.lastname: Poligone
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007378:Interleukins / Q000009:adverse effects / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D009182:Mycosis Fungoides / Q000188:drug therapy; D061988:Proteasome Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D012751:Sezary Syndrome / Q000188:drug therapy; D012878:Skin Neoplasms / Q000188:drug therapy*; D059003:Topoisomerase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D007378:Interleukins; D061988:Proteasome Inhibitors; D059003:Topoisomerase Inhibitors
keywords: Chemotherapy; Clinical trial; Response rate